Bimagrumab is under clinical development by Versanis Bio and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bimagrumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bimagrumab overview

Bimagrumab (BYM-338) is under development for the treatment of non-diabetic patients with obesity. Bimagrumab is administered as an intravenous infusion. It is a fully human HuCAL-based antibody which targets ActRIIB (activin receptor type-2B). It was also under development for cachexia in patients with chronic obstructive pulmonary disorder, type 2 diabtetes, stage IV non-small cell lung cancer or stage III/IV adenocarcinoma of the pancreas, musculoskeletal diseases such as sporadic inclusion body myositis (sIBM), hip fracture, sarcopenia, disuse muscle atrophy associated with femoral fracture.

Versanis Bio overview

Versanis Bio (Versanis) is a biopharmaceutical company that develops therapeutics for obesity and cardiometabolic diseases. The company’s lead product candidate bimagrumab, a first-in-class monoclonal antibody that blocks activin type two receptors and directly targets fat and muscle tissues. Its product works for treatment of obesity and to maintain both substantial fat loss and healthy body composition. The company serves pharmaceutical and health care sectors. Versanis is headquartered in New York, the US.

For a complete picture of Bimagrumab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.